<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(2)</volume><submitter>Odeh-Couvertier VY</submitter><pubmed_abstract>Large-scale, reproducible manufacturing of therapeutic cells with consistently high quality is vital for translation to clinically effective and widely accessible cell therapies. However, the biological and logistical complexity of manufacturing a living product, including challenges associated with their inherent variability and uncertainties of process parameters, currently make it difficult to achieve predictable cell-product quality. Using a degradable microscaffold-based T-cell process, we developed an artificial intelligence (AI)-driven experimental-computational platform to identify a set of critical process parameters and critical quality attributes from heterogeneous, high-dimensional, time-dependent multiomics data, measurable during early stages of manufacturing and predictive o</pubmed_abstract><journal>Bioengineering &amp; translational medicine</journal><pagination>e10282</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9115702</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Predicting T-cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform.</pubmed_title><pmcid>PMC9115702</pmcid><pubmed_authors>Roy K</pubmed_authors><pubmed_authors>Colonna MB</pubmed_authors><pubmed_authors>Torres-Garcia W</pubmed_authors><pubmed_authors>Odeh-Couvertier VY</pubmed_authors><pubmed_authors>Levine BL</pubmed_authors><pubmed_authors>Dwarshuis NJ</pubmed_authors><pubmed_authors>Edison AS</pubmed_authors><pubmed_authors>Kotanchek T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Predicting T-cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform.</name><description>Large-scale, reproducible manufacturing of therapeutic cells with consistently high quality is vital for translation to clinically effective and widely accessible cell therapies. However, the biological and logistical complexity of manufacturing a living product, including challenges associated with their inherent variability and uncertainties of process parameters, currently make it difficult to achieve predictable cell-product quality. Using a degradable microscaffold-based T-cell process, we developed an artificial intelligence (AI)-driven experimental-computational platform to identify a set of critical process parameters and critical quality attributes from heterogeneous, high-dimensional, time-dependent multiomics data, measurable during early stages of manufacturing and predictive o</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2025-04-18T13:16:37.853Z</modification><creation>2024-11-06T08:32:28.89Z</creation></dates><accession>S-EPMC9115702</accession><cross_references><pubmed>35600660</pubmed><doi>10.1002/btm2.10282</doi></cross_references></HashMap>